FMR LLC 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-07 10:23 am Sale | 2025-01-31 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 704,472 1.700% | -3,169,732 (-81.82%) | Filing |
| 2024-02-09 09:16 am Purchase | 2024-02-08 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 3,874,204 12.931% | 195,115 (+5.30%) | Filing |
| 2023-02-09 12:48 pm Purchase | 2023-02-09 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 3,679,089 13.357% | 174,291 (+4.97%) | Filing |
| 2022-02-09 09:22 am Purchase | 2022-02-08 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 3,504,798 14.978% | 860,178 (+32.53%) | Filing |
| 2021-02-08 10:25 am Sale | 2021-02-05 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 2,644,620 11.411% | -381,261 (-12.60%) | Filing |
| 2020-11-10 10:27 am Purchase | 2020-11-09 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 3,025,881 14.999% | 3,025,881 (New Position) | Filing |